Alembic Limited reports 11.8% net profit decline in Q1FY26
Alembic Limited's Q1FY26 results show a decline in both top-line and bottom-line figures. Net profit dropped to ₹157 crore from ₹178 crore, and revenue decreased slightly to ₹487 crore. The most significant impact was seen in EBITDA, which fell nearly 21% to ₹155 crore, causing margins to compress by over 700 basis points. The API segment turned profitable, offsetting some losses, but overall operating efficiency declined.

*this image is generated using AI for illustrative purposes only.
Alembic Limited reported a consolidated net profit of ₹157 crore for the quarter ended June 30, 2026, marking an 11.8% decline from ₹178 crore in the corresponding period of the previous year. Revenue from operations contracted modestly by 2% to ₹487 crore, down from ₹497 crore year-on-year. The pressure on profitability was more pronounced in operating metrics, with EBITDA falling 20.9% to ₹155 crore and EBITDA margin compressing by 728 basis points to 31.72% from 39.00%. This margin contraction highlights significant headwinds in the company’s core operating segments during the initial quarter of FY26.
The Board of Directors approved the unaudited financial results on August 11, 2026, following a review by the Audit Committee. The results were reviewed pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by the statutory auditors, C N K & Associates LLP. The Board meeting commenced at 3:30 p.m. and concluded at 4:00 p.m. on that date.
Consolidated Financial Performance
The latest quarterly results reflect year-on-year pressure across key financial metrics. While revenue remained relatively stable, the sharp decline in EBITDA indicates a compression in operating leverage or higher input costs relative to sales. The following table summarises the key consolidated performance indicators:
| Metric: | Latest Quarter | Year-Ago Quarter | Change |
|---|---|---|---|
| Revenue from Operations: | ₹487 crore | ₹497 crore | -2.01% |
| EBITDA: | ₹155 crore | ₹196 crore | -20.92% |
| EBITDA Margin: | 31.72% | 39.00% | -728 bps |
| Net Profit: | ₹157 crore | ₹178 crore | -11.80% |
Segment-wise Breakdown
The Real Estate Business remained the primary revenue driver for Alembic, contributing ₹3,703 lakh in the latest quarter, compared to ₹3,680 lakh in the year-ago period. The Active Pharmaceutical Ingredients (API) Business saw revenue decline to ₹1,171 lakh from ₹1,295 lakh in the prior year quarter. However, the API segment returned to profitability with a segment result of ₹166 lakh, reversing a loss of ₹117 lakh in the previous quarter.
Auditor's Emphasis of Matter
Statutory auditors C N K & Associates LLP included an emphasis of matter regarding a disputed electricity duty liability. The company has provided ₹2,052.13 lakh towards the principal amount of the dispute filed against the State of Gujarat. The interest remains unascertainable and is disclosed as a contingent liability. The company deposited ₹35 crore with the Supreme Court on May 26, 2023, and its appeal has been admitted.
Historical Stock Returns for Alembic
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.04% | -5.04% | -6.40% | -15.16% | -22.78% | -22.35% |
What specific cost drivers or operational inefficiencies contributed to the 728 basis point compression in EBITDA margins despite relatively stable revenue?
How sustainable is the API segment's return to profitability, and what strategic initiatives are in place to reverse the year-on-year revenue decline in this division?
What is the projected timeline for the resolution of the disputed electricity duty liability, and how might a final verdict impact the company's cash flow and contingent liabilities?


































